In the past, we have written about Xeljanz-related blood clots and Xeljanz pulmonary embolism risks, i.e., blood clots in the lung, which can lead to death in some cases. Recently, however, we saw there are some new clinical trial findings of serious infections linked to Xeljanz. In March 2020 the UK’s Medicines and Healthcare products … [Read more...]
EU Calls for Strengthened and Revised Warnings for MS Drug Gilenya
UPDATE: On December 15, 2017, the FDA released an updated drug label for Gilenya with increased warnings. (12/27/17). Background After conducting a routine review of the immunosuppressive drug Gilenya (fingolimod), the Medicines and Healthcare Products Regulatory Agency (MHRA) recently suggested that the drug label for Gilenya be … [Read more...]